GenVec About
GenVec GenVec, Inc. (Nasdaq: GNVC) is a clinical-stage
biopharmaceutical company developing innoative
gene-based therapeutics to treat cancer,
heart disease and ophthalmic disorders.
Each of GenVec's gene-based product candidates
uses a common patent-protected technology
platform to deliver genes. GenVec, Inc. is a clinical-stage biopharmaceutical
company developing and working to commercialize
therapeutic proteins to treat serious
and life-threatening diseases, including
cancer, heart disease and diseases of
the eye. TNFerade,
which is in three Phase II trials for
the treatment of locally advanced pancreatic
cancer, non-metastatic esophageal
cancer and rectal cancer.TNFerade™
represents a novel approach to treating
cancer in combination with radiation and/or
chemotherapy by delivering tumor necrosis
factor-alpha (TNF-alpha), a potent anti-cancer
protein, directly into tumors.
BIOBYPASS,
which has completed a Phase II trial in
71 patients with severe heart disease
that have no treatment options. BIOBYPASS®
promotes production of vascular endothelial
growth factor (VEGF) protein to stimulate
the growth of new blood vessels in areas
of the heart lacking sufficient blood
flow. AdPEDF,
which is in a Phase I trial for the treatment
of wet age-related macular degeneration,
a cause of blindness in individuals over
the age of 50. More
on GenVec Key
Statistics for GenVec
Basic
Chart for GenVec